Treatment | Initial response* (days)[1] | Peak response¶ (days)[1] | Initial response rate | Toxicities/risks | Sustained response |
First-line options for newly diagnosed or persistent ITP | |||||
Watchful waiting | A few days to 3 to 6 months | Spontaneous complete remission occurs in 50% within one month of presentation and 75% by six months | Risk of preventable hemorrhage (low risk); need for activity restriction; familial anxiety. | Relapse after spontaneous remission is unlikely. | |
IVIGΔ Life-threatening bleeding: 1 gram/kg per day IV for one to three days
Non-life-threatening bleeding: 0.8 to 1 gram/kg IV, as a single dose | 1 to 3 | 2 to 7 | Initially effective in >80% of patients | Side effects include headache (can be severe [eg, aseptic meningitis]), nausea, vomiting, fever, chills, body aches. These can be minimized with premedication and prolonging infusion time.Δ Transient neutropenia also may occur. | One-third of patients fall below acceptable platelet threshold after 2 to 6 weeks. |
Anti-DΔ◊ 75 micrograms/kg IV, as a single dose | 1 to 3 | 3 to 7 | Initially effective in 70 to 80% | Headache (less common than with IVIG), fever, chills, nausea, and vomiting. Side effects may be reduced with premedication.Δ Mild hemolysis is common (eg, fall in hemoglobin by 1 to 2 g/dL). DIC and severe hemolysis or renal failure may rarely occur. Anti-D is contraindicated in patients who are Rh-negative or DAT-positive, or have had splenectomy. | Similar to IVIG, although longer responses have been described with repeat dosing. |
Methylprednisolone 30 mg/kg as a single daily dose IV for 3 to 4 days (maximum 1000 mg per day) | 2 to 14 | 7 to 28 | Initially effective in 75 to 80% | Behavioral change, sleep disturbance, hypertension, impaired glucose tolerance. | In one-quarter to one-third of patients, platelet counts fall below acceptable thresholds after 2 to 6 weeks. |
Prednisone 4 mg/kg per day orally for 7 days, followed by rapid tapering§ (maximum 240 mg/day) | 4 to 14 | 7 to 28 | Initially effective in up to 75% | Same as for methylprednisolone above. Prolonged usage may cause weight gain, osteopenia, cataracts, and growth failure. | In many patients, platelet counts fall below acceptable platelet thresholds after tapering, unless the course of prednisone is prolonged. |
Dexamethasone 24 mg/m2 for 4 days orally or IV§ (maximum 40 mg/day) | 2 to 14 | 4 to 28 | Initially effective in up to 75% | Same as for methylprednisolone above. | In one-third of patients, platelet counts fall below acceptable thresholds after 2 to 6 weeks. |
Second-line options for chronic ITP | |||||
Rituximab[3] 375 mg/m2 weekly for four weeks | 7 to 56 | 14 to 180 | Initial response in 40 to 50% | Urticarial rash, headache, fever, and chills (mild and transient). Serum sickness in up to 10% of children. | 25% long-term response (2 or more years after treatment). |
Thrombopoietin receptor agonists (eg, eltrombopag[4], romiplostim[5])¥ | 5 to 7 | Not established | Approximately 80% of patients achieve a response | Transaminitis, mild respiratory illness, headache, epistaxis, cataract (rare). | The response lasts only as long as the drug is continued; these drugs do not typically induce remission. |
Splenectomy | 1 to 56 | 7 to 56 | 60 to 70% long-term response | Complications include sepsis and portal vein thrombosis. | 70 to 80% of responders maintain platelet response over 4 years. |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟